Recent advancements regarding the field of diabetes treatment have brought about a significant class of medications known as GLP-1 and GIP receptor agonists. These agents provide a unique mechanism of action by enhancing the receptors for both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). This dual targetin